Information  X 
Enter a valid email address

Evgen Pharma PLC (EVG)

  Print      Mail a friend

Thursday 18 April, 2019

Evgen Pharma PLC

Posting of Circular and Timing of General Meeting

RNS Number : 6836W
Evgen Pharma PLC
18 April 2019
 

Evgen Pharma plc

("Evgen Pharma", or the "Company")

 

Posting of Circular

and

Timing of General Meeting

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that further to its announcement of the Placing yesterday (the "Placing Announcement"), a shareholder circular, including the notice of General Meeting, and a form of proxy are today being posted to shareholders. The shareholder circular and notice of General Meeting will be made available on the Company's website www.evgen.com

Furthermore, since the posting of the Placing Announcement yesterday, the timing of the General Meeting has been changed and will now take place on 8 May 2019 at 11.00 a.m. at the offices of finnCap, 60 New Broad Street, London EC2M 1JJ.

Capitalised terms used in this announcement shall have the same meanings as the definitions in the Placing Announcement.

 

For further information please visit www.evgen.com or contact:

 

Evgen Pharma plc

Dr Stephen Franklin, CEO

Richard Moulson, CFO

www.evgen.com

 

c/o +44 (0) 20 7466 5000

finnCap

Geoff Nash, Teddy Whiley (Corporate Finance)

Alice Lane, Manasa Patil (ECM)

www.finncap.com

 

  +44 (0) 20 7220 0500 

WG Partners LLP

Nigel Barnes, Claes Spång

 

+44 (0) 20 3705 9330

Buchanan

Mark Court, Sophie Wills, Tilly Abraham

[email protected]

 

 +44 (0) 20 7466 5000

 

 

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com  


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCBSGDSCDBBGCI

a d v e r t i s e m e n t